Post-inflammatory pulmonary fibrosis in a discharged COVID-19 patient: Effectively treated with Pirfenidone

<p>The coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) has led to a pandemic situation. According to the WHO classification, COVID-19 patients could be classified with severity as uncomplicated illness, mild pneumonia, severe pneumonia,...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Zhan Xi (लेखक), Zhao Zhigang (लेखक), Li Ting (लेखक)
स्वरूप: पुस्तक
प्रकाशित: Archives of Pulmonology and Respiratory Care - Peertechz Publications, 2020-06-23.
विषय:
ऑनलाइन पहुंच:Connect to this object online.
टैग: टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
विवरण
सारांश:<p>The coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) has led to a pandemic situation. According to the WHO classification, COVID-19 patients could be classified with severity as uncomplicated illness, mild pneumonia, severe pneumonia, acute respiratory distress syndrome (ARDS), sepsis, and septic shock [1]. China has controlled the situation and thousands of patients had been discharged. We noticed that most patients of severe pneumonia or ARDS had post-inflammatory pulmonary fibrosis (PPF) during follow-up after the cure of COVID-19. Here we report a case of PPF resulting from COVID-19 effectively treated with Pirfenidone, an antifibrosis medication. </p><p><br></p>
डिजिटल ऑब्जेक्ट पहचानकर्ता:10.17352/aprc.000053